Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298672 | 0.81 | CHRM2 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL24909178 | 0.78 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL13689075 | 0.77 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4301758 | 0.77 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4301341 | 0.76 | CTSK (0.35) | NR1H2CHRM2CHRM1CHRM3AR | |
| SCHEMBL24909180 | 0.74 | TACR1 (0.31) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24909176 | 0.73 | ALDH1A1 (0.32) | NR1H2 | |
| SCHEMBL1338596 | 0.72 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3AR | |
| SCHEMBL24909275 | 0.72 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3AR | |
| SCHEMBL2926520 | 0.72 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, CYP17A1 | NR1H2 36/4885CHRM2 2055/4885CHRM1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.